2.81
+0.01(+0.36%)
Currency In USD
| Previous Close | 2.8 |
| Open | 2.79 |
| Day High | 2.83 |
| Day Low | 2.52 |
| 52-Week High | 3.07 |
| 52-Week Low | 0.36 |
| Volume | 3.99M |
| Average Volume | 7.82M |
| Market Cap | 372.97M |
| PE | -6.24 |
| EPS | -0.45 |
| Moving Average 50 Days | 2.13 |
| Moving Average 200 Days | 1.16 |
| Change | 0.01 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $134.58 as of December 25, 2025 at a share price of $2.81. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $1,860.93 as of December 25, 2025 at a share price of $2.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
GlobeNewswire Inc.
Dec 23, 2025 12:05 PM GMT
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal anti
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
GlobeNewswire Inc.
Dec 23, 2025 12:01 PM GMT
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three mon
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 12:01 PM GMT
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in M